45 results on '"Arnall, Justin R."'
Search Results
2. Real-world clinical outcomes with fostamatinib for the treatment of refractory chronic immune thrombocytopenia: a single-center experience.
3. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review
4. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant
5. Comparative Utilization and Efficacy of Thrombopoietin Receptor Agonists in Relapsed/Refractory Immune Thrombocytopenia
6. Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease.
7. Real-world Experience of Caplacizumab for Adolescents in the First-line Setting: Case Reports
8. Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner.
9. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease–Associated Hemolysis.
10. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease–Associated Hemolysis
11. Measuring the Impact of a Pharmacist-Driven Blood Factor Education Program: A Prospective, Single-Center Observational Study
12. Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease
13. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system
14. Recombinant von Willebrand factor for perioperative bleeding management in pediatric patient with allergy to plasma‐derived von Willebrand factor
15. Immune checkpoint inhibitor‐induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system
16. Measuring the Impact of a Pharmacist-Driven Blood Factor Education Program: A Prospective, Single-Center Observational Study.
17. Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations
18. Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.
19. Publication rates of hematology/oncology abstracts presented at major pharmacy association meetings.
20. Publication rates of hematology/oncology abstracts presented at major pharmacy association meetings
21. Letter to the editor concerning “Single-institution experience of performing bloodless transplant in Jehovah’s Witness patients” by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol oncol stem cell ther 2019;12(1):44–9.)
22. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia
23. Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis
24. Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol
25. Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure
26. Caplacizumab: an anti–von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura
27. Necessity of pharmacist-driven nonprescription telehealth consult services in the era of COVID-19
28. Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis.
29. Critical Care University of South Dakota Sanford School of Medicine, Sioux Falls, SD.
30. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
31. Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support.
32. Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support
33. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses
34. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report
35. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement
36. Transitioning historically inpatient chemotherapy regimens for hematologic malignancies to the ambulatory care setting
37. Implementation of a longitudinal early immersion student pharmacist health system internship program
38. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab.
39. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma
40. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice
41. Recombinant von Willebrand factor for perioperative bleeding management in pediatric patient with allergy to plasma‐derived von Willebrand factor.
42. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
43. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
44. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
45. Letter to the editor concerning “Single-institution experience of performing bloodless transplant in Jehovah’s Witness patients” by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol oncol stem cell ther2019;12(1):44–9.)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.